News | May 24, 2025
Strides Pharma Q4 net profit rises 5x to Rs. 113 Cr
For the full year FY25, net profit soared 12x to Rs 345 crore
For the full year FY25, net profit soared 12x to Rs 345 crore
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
PAT rises to Rs 195.76 crore
Among the growth drivers are biosimilars business, operational efficiencies, and integration of biosimilars and generics operations
Subscribe To Our Newsletter & Stay Updated
